Table 3 Comparison of commonly used allogeneic NK cell sources
From: NK cell-based cancer immunotherapy: from basic biology to clinical development
NK source | Advantages | Limitations |
|---|---|---|
PB-NK cells | Relatively easy to collect Good in vivo expansion Good clinical track record | Heterogeneous cell population Challenging to genetically modify Can only give one dose |
UB-NK cells | NK Progenitors and CD34 + present Higher percentage of NK cells The ability to cryopreserve UCB | Heterogeneous cell population |
NK92 cells | Defined, homogeneous cell population Easy to expand Easy to genetically modify Can give multiple doses | Tumor cells Irradiated Lack certain receptors, e.g., CD16 limited in vivo expansion |
iPSC-NK cells | Defined, homogeneous cell population Circumvent issues with donor sourced cells (donor selection, contaminating T, B) Potential for in depth preclinical testing Defined genetic makeup Easy to genetically modify at iPSC stage Can give multiple doses Can engineer multiple enhancements Don’t need to irradiate- good in vivo survival Suitable for “off-the-shelf” multicancer NK cell therapy | More complicated to produce |